Agree. If 10% market share is already giving us A$0.89 per share, imagine 30% or 50%... They also applied a 30% probability on future cashflows post commercialization so I assume the NPV will be more than tripled if the drug does get approved for ALS/MND.
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3, page-33
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.00M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.3¢ | $112.4K | 570.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 71364 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 457262 | 6 |
View Market Depth
| Last trade - 15.59pm 05/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |